Suppr超能文献

膳食建议,包括或不包括口服营养补充剂,用于治疗成人相关营养不良。

Dietary advice with or without oral nutritional supplements for disease-related malnutrition in adults.

机构信息

Department of Nutritional Sciences, Facutly of Life Sciences & Medicine, King's College London, London, UK.

Department of Nutrition, Dietetics and Lifestyle, HAN University of Applied Sciences, Nijmegen, Netherlands.

出版信息

Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD002008. doi: 10.1002/14651858.CD002008.pub5.

Abstract

BACKGROUND

Disease-related malnutrition has been reported in 10% to 55% of people in hospital and the community and is associated with significant health and social-care costs. Dietary advice (DA) encouraging consumption of energy- and nutrient-rich foods rather than oral nutritional supplements (ONS) may be an initial treatment.

OBJECTIVES

To examine evidence that DA with/without ONS in adults with disease-related malnutrition improves survival, weight, anthropometry and quality of life (QoL).

SEARCH METHODS

We identified relevant publications from comprehensive electronic database searches and handsearching. Last search: 01 March 2021.

SELECTION CRITERIA

Randomised controlled trials (RCTs) of DA with/without ONS in adults with disease-related malnutrition in any healthcare setting compared with no advice, ONS or DA alone.

DATA COLLECTION AND ANALYSIS

Two authors independently assessed study eligibility, risk of bias, extracted data and graded evidence.

MAIN RESULTS

We included 94, mostly parallel, RCTs (102 comparisons; 10,284 adults) across many conditions possibly explaining the high heterogeneity.  Participants were mostly older people in hospital, residential care and the community, with limited reporting on their sex. Studies lasted from one month to 6.5 years.  DA versus no advice - 24 RCTs (3523 participants) Most outcomes had low-certainty evidence. There may be little or no effect on mortality after three months, RR 0.87 (95% confidence interval (CI) 0.26 to 2.96), or at later time points. We had no three-month data, but advice may make little or no difference to hospitalisations, or days in hospital after four to six months and up to 12 months. A similar effect was seen for complications at up to three months, MD 0.00 (95% CI -0.32 to 0.32) and between four and six months. Advice may improve weight after three months, MD 0.97 kg (95% CI 0.06 to 1.87) continuing at four to six months and up to 12 months; and may result in a greater gain in fat-free mass (FFM) after 12 months, but not earlier. It may also improve global QoL at up to three months, MD 3.30 (95% CI 1.47 to 5.13), but not later. DA versus ONS - 12 RCTs (852 participants) All outcomes had low-certainty evidence. There may be little or no effect on mortality after three months, RR 0.66 (95% CI 0.34 to 1.26), or at later time points. Either intervention may make little or no difference to hospitalisations at three months, RR 0.36 (95% CI 0.04 to 3.24), but ONS may reduce hospitalisations up to six months. There was little or no difference between groups in weight change at three months, MD -0.14 kg (95% CI -2.01 to 1.74), or between four to six months. Advice (one study) may lead to better global QoL scores but only after 12 months. No study reported days in hospital, complications or FFM. DA versus DA plus ONS - 22 RCTs (1286 participants) Most outcomes had low-certainty evidence. There may be little or no effect on mortality after three months, RR 0.92 (95% CI 0.47 to 1.80) or at later time points. At three months advice may lead to fewer hospitalisations, RR 1.70 (95% CI 1.04 to 2.77), but not at up to six months. There may be little or no effect on length of hospital stay at up to three months, MD -1.07 (95% CI -4.10 to 1.97). At three months DA plus ONS may lead to fewer complications, RR 0.75 (95% CI o.56 to 0.99); greater weight gain, MD 1.15 kg (95% CI 0.42 to 1.87); and better global QoL scores, MD 0.33 (95% CI 0.09 to 0.57), but this was not seen at other time points. There was no effect on FFM at three months. DA plus ONS if required versus no advice or ONS - 31 RCTs (3308 participants) Evidence was moderate- to low-certainty. There may be little or no effect on mortality at three months, RR 0.82 (95% CI 0.58 to 1.16) or at later time points. Similarly, little or no effect on hospitalisations at three months, RR 0.83 (95% CI 0.59 to 1.15), at four to six months and up to 12 months; on days in hospital at three months, MD -0.12 (95% CI -2.48 to 2.25) or for complications at any time point. At three months, advice plus ONS probably improve weight, MD 1.25 kg (95% CI 0.73 to 1.76) and may improve FFM, 0.82 (95% CI 0.35 to 1.29), but these effects were not seen later. There may be little or no effect of either intervention on global QoL scores at three months, but advice plus ONS may improve scores at up to 12 months. DA plus ONS versus no advice or ONS - 13 RCTs (1315 participants) Evidence was low- to very low-certainty. There may be little or no effect on mortality after three months, RR 0.91 (95% CI 0.55 to 1.52) or at later time points. No study reported hospitalisations and there may be little or no effect on days in hospital after three months, MD -1.81 (95% CI -3.65 to 0.04) or six months. Advice plus ONS may lead to fewer complications up to three months, MD 0.42 (95% CI 0.20 to 0.89) (one study). Interventions may make little or no difference to weight at three months, MD 1.08 kg (95% CI -0.17 to 2.33); however, advice plus ONS may improve weight at four to six months and up to 12 months. Interventions may make little or no difference in FFM or global QoL scores at any time point.

AUTHORS' CONCLUSIONS: We found no evidence of an effect of any intervention on mortality. There may be weight gain with DA and with DA plus ONS in the short term, but the benefits of DA when compared with ONS are uncertain. The size and direction of effect and the length of intervention and follow-up required for benefits to emerge were inconsistent for all other outcomes.  There were too few data for many outcomes to allow meaningful conclusions. Studies focusing on both patient-centred and healthcare outcomes are needed to address the questions in this review.

摘要

背景

据报道,10%至 55%的住院患者和社区患者存在与疾病相关的营养不良,且这种营养不良与显著的健康和社会保健费用有关。与口服营养补充剂(ONS)相比,鼓励摄入能量和营养丰富的食物的饮食建议(DA)可能是一种初始治疗方法。

目的

检查成人疾病相关营养不良患者使用 DA 联合/不联合 ONS 是否能改善生存率、体重、人体测量学和生活质量(QoL)。

检索方法

我们从综合电子数据库搜索和手工搜索中确定了相关出版物。最后一次搜索日期:2021 年 3 月 1 日。

选择标准

在任何医疗保健环境中,与无建议、ONS 或单独 DA 相比,对成人疾病相关营养不良患者使用 DA 联合/不联合 ONS 的随机对照试验(RCT)。

数据收集和分析

两名作者独立评估了研究的纳入标准、偏倚风险、提取数据和分级证据。

主要结果

我们纳入了 94 项主要为平行的 RCT(102 项比较;10284 名成年人),涉及多种可能导致高异质性的疾病。参与者主要是住院、长期护理和社区的老年人,其性别报告有限。研究持续时间从一个月到 6.5 年不等。

  • DA 与无建议-24 项 RCT(3523 名参与者)

大多数结局的证据质量为低或非常低。在三个月时,可能对死亡率没有或仅有很小的影响,RR0.87(95%CI0.26 至 2.96),或在更晚的时间点。我们没有三个月的数据,但在三个月、四个至六个月和长达 12 个月的时间点,建议可能对住院或住院天数没有或仅有很小的影响。同样,在三个月、四个至六个月和长达 12 个月的时间点,并发症的效果也相似,MD0.00(95%CI-0.32 至 0.32)。在三个月时,建议可能会使体重增加,MD0.97kg(95%CI0.06 至 1.87),并持续到四个至六个月和长达 12 个月;并且可能导致在 12 个月后脂肪量(FFM)增加,但不是更早。它还可能在三个月时改善全球 QoL,MD3.30(95%CI1.47 至 5.13),但不是在以后。

  • DA 与 ONS-12 项 RCT(852 名参与者)

所有结局的证据质量为低或非常低。在三个月时,可能对死亡率没有或仅有很小的影响,RR0.66(95%CI0.34 至 1.26),或在更晚的时间点。任何一种干预措施可能对三个月时的住院没有或仅有很小的影响,RR0.36(95%CI0.04 至 3.24),但 ONS 可能减少六个月时的住院。两组之间在三个月时的体重变化、MD-0.14kg(95%CI-2.01 至 1.74),或在四个至六个月时,没有差异。一项研究报告说,建议可能会导致更好的全球 QoL 评分,但只有在 12 个月后。没有研究报告住院天数、并发症或 FFM。

  • DA 与 DA 加 ONS-22 项 RCT(1286 名参与者)

大多数结局的证据质量为低或非常低。在三个月时,可能对死亡率没有或仅有很小的影响,RR0.92(95%CI0.47 至 1.80),或在更晚的时间点。在三个月时,建议可能会导致更少的住院,RR1.70(95%CI1.04 至 2.77),但在长达六个月时没有。在三个月时,建议可能会导致住院天数减少,MD-1.07(95%CI-4.10 至 1.97)。在三个月时,DA 加 ONS 可能会导致并发症更少,RR0.75(95%CI0.56 至 0.99);体重增加更多,MD1.15kg(95%CI0.42 至 1.87);全球 QoL 评分更高,MD0.33(95%CI0.09 至 0.57),但在其他时间点没有看到。三个月时 FFM 没有变化。

  • DA 加 ONS(如果需要)与无建议或 ONS-31 项 RCT(3308 名参与者)

证据为中等到低质量。在三个月时,可能对死亡率没有或仅有很小的影响,RR0.82(95%CI0.58 至 1.16),或在更晚的时间点。同样,在三个月、四个至六个月和长达 12 个月时,住院或住院天数的影响很小或没有,RR0.83(95%CI0.59 至 1.15);在三个月时,住院天数减少,MD-0.12(95%CI-2.48 至 2.25)或并发症任何时间点。在三个月时,建议加 ONS 可能会改善体重,MD1.25kg(95%CI0.73 至 1.76),并可能改善 FFM,0.82(95%CI0.35 至 1.29),但这些效果在以后没有看到。在三个月时,任何一种干预措施对全球 QoL 评分的影响可能很小,但建议加 ONS 可能会在长达 12 个月的时间里改善评分。

  • DA 加 ONS 与无建议或 ONS-13 项 RCT(1315 名参与者)

证据质量为低至非常低。在三个月时,可能对死亡率没有或仅有很小的影响,RR0.91(95%CI0.55 至 1.52),或在更晚的时间点。没有研究报告住院,在三个月或六个月时,可能对住院天数没有或仅有很小的影响,MD-1.81(95%CI-3.65 至 0.04)。在三个月时,建议加 ONS 可能会导致并发症更少,MD0.42(95%CI0.20 至 0.89)(一项研究)。干预措施可能对三个月时的体重没有或仅有很小的影响,MD1.08kg(95%CI-0.17 至 2.33);然而,DA 加 ONS 可能会在四个至六个月和长达 12 个月时改善体重。干预措施可能对 FFM 或全球 QoL 评分没有影响。

作者结论

我们没有发现任何干预措施对死亡率有影响。DA 和 DA 加 ONS 在短期内可能会增加体重,但 DA 与 ONS 相比的获益尚不确定。所有其他结局的效果大小、方向以及获益所需的干预和随访时间长短均不一致。对于许多结局,数据太少,无法得出有意义的结论。需要进行以患者为中心和以医疗保健为重点的结局为重点的研究来解决本综述中的问题。

相似文献

1
Dietary advice with or without oral nutritional supplements for disease-related malnutrition in adults.
Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD002008. doi: 10.1002/14651858.CD002008.pub5.
2
Interventions for preventing weight gain after smoking cessation.
Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4.
3
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
4
Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD).
Cochrane Database Syst Rev. 2021 Jul 20;7(7):CD013196. doi: 10.1002/14651858.CD013196.pub2.
6
Sertindole for schizophrenia.
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
7
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.
9
Effects of total fat intake on bodyweight in children.
Cochrane Database Syst Rev. 2018 Jul 5;7(7):CD012960. doi: 10.1002/14651858.CD012960.pub2.
10
Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth.
Cochrane Database Syst Rev. 2022 Aug 9;8(8):CD006764. doi: 10.1002/14651858.CD006764.pub4.

引用本文的文献

5
Call to Improve Coding of Cancer-Associated Cachexia.
JCO Oncol Pract. 2025 Jul;21(7):926-931. doi: 10.1200/OP-24-00781. Epub 2025 Jan 13.
7
Addressing the malnutrition gap requires high-quality research, recognition of intervention complexity, and equitable implementation strategies.
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1015-1018. doi: 10.21037/hbsn-24-482. Epub 2024 Nov 13.
10
Overall mortality for community-dwelling adults over 50 years at risk of malnutrition.
J Cachexia Sarcopenia Muscle. 2024 Dec;15(6):2509-2518. doi: 10.1002/jcsm.13585. Epub 2024 Aug 29.

本文引用的文献

1
Effect of long-term aggressive nutrition therapy on survival in patients with alcohol-related cirrhosis: A randomized controlled trial.
Indian J Gastroenterol. 2022 Feb;41(1):52-62. doi: 10.1007/s12664-021-01187-3. Epub 2022 Mar 2.
4
Effectiveness of renal-specific oral nutritional supplements compared with diet counseling in malnourished hemodialysis patients.
Int Urol Nephrol. 2021 Aug;53(8):1675-1687. doi: 10.1007/s11255-020-02768-5. Epub 2021 Jan 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验